|
Lilly Discontinues Phase III Rheumatoid Arthritis Program
|
|
|
| By
Amy Ritter
|
|
|
|
Eli Lilly and Co. announced that it will discontinue its Phase III rheumatoid arthritis program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, because of lack of efficacy.
|
|
|
|
Drug Discovery Initiative Launched in Europe
|
|
|
| By
Stephanie Sutton
|
|
|
|
An international consortium of pharmaceutical companies, academia, research organisations and other related entities have launched a new platform to help enhance drug discovery in Europe.
|
|
|
|
GSK Announces Fourth Quarter 2012 Results and 2013 Plans
|
|
|
| By
Jennifer Markarian
|
|
|
|
Group sales were down, but R&D progress points to future growth.
|
|
|
|
Biogen Acquires Full Tysabri Rights from Elan
|
|
|
| By
Christopher Allen
|
|
|
|
Biogen Idec has agreed to acquire full Tysabri rights from Elan, and will use its existing cash reserves to make a payment of $3.25 billion to Elan upon the closing of the transaction and make future contingent payments to Elan.
|
|
|
|
Lycera and MSD Collaborate on Autoimmune Therapies
|
|
|
| By
Stephanie Sutton
|
|
|
|
The biopharmaceutical company lycera has announced a collaboration agreement with Merck, Sharpe & Dohme (MSD) that will focus on developing and commercializing small-molecule therapies for treating a range of autoimmune diseases.
|
|
|
|
Industry Briefs: February 11, 2013
|
|
|
|
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
|
|
|
